 Tin Su
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drosophila melanogaster | 28 | 2024 | 200 | 8.050 |
Why?
| | Drosophila Proteins | 22 | 2022 | 171 | 5.920 |
Why?
| | Drosophila | 16 | 2019 | 140 | 4.810 |
Why?
| | Radiation, Ionizing | 12 | 2020 | 74 | 2.640 |
Why?
| | Cell Cycle | 17 | 2020 | 550 | 2.420 |
Why?
| | Regeneration | 6 | 2022 | 165 | 2.310 |
Why?
| | Apoptosis | 15 | 2022 | 2484 | 2.170 |
Why?
| | DNA Damage | 15 | 2020 | 357 | 1.730 |
Why?
| | Caspases | 4 | 2020 | 269 | 1.650 |
Why?
| | Imaginal Discs | 5 | 2019 | 5 | 1.560 |
Why?
| | Wings, Animal | 7 | 2022 | 33 | 1.440 |
Why?
| | Wnt1 Protein | 3 | 2022 | 8 | 1.430 |
Why?
| | Mitosis | 10 | 2011 | 172 | 1.420 |
Why?
| | Tumor Suppressor Protein p53 | 6 | 2020 | 455 | 1.290 |
Why?
| | STAT Transcription Factors | 2 | 2017 | 15 | 1.200 |
Why?
| | Neoplasms | 6 | 2023 | 2179 | 1.200 |
Why?
| | Cell Cycle Proteins | 10 | 2017 | 565 | 1.180 |
Why?
| | High-Throughput Screening Assays | 2 | 2023 | 122 | 1.170 |
Why?
| | Animals | 56 | 2024 | 33381 | 1.140 |
Why?
| | Stem Cells | 3 | 2018 | 559 | 1.060 |
Why?
| | Chromosomes | 2 | 2024 | 87 | 1.010 |
Why?
| | Loss of Heterozygosity | 2 | 2024 | 40 | 1.010 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 260 | 0.990 |
Why?
| | Cell Death | 5 | 2018 | 339 | 0.940 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2015 | 38 | 0.920 |
Why?
| | Radiation Tolerance | 3 | 2014 | 98 | 0.910 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 81 | 0.900 |
Why?
| | Larva | 8 | 2022 | 213 | 0.870 |
Why?
| | Spindle Apparatus | 6 | 2011 | 86 | 0.870 |
Why?
| | Models, Biological | 11 | 2020 | 1715 | 0.860 |
Why?
| | Drug Discovery | 2 | 2023 | 124 | 0.850 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2021 | 404 | 0.790 |
Why?
| | Wound Healing | 1 | 2023 | 270 | 0.780 |
Why?
| | Gene Expression Profiling | 2 | 2022 | 1597 | 0.770 |
Why?
| | DNA Repair | 6 | 2020 | 198 | 0.760 |
Why?
| | Embryo, Nonmammalian | 5 | 2011 | 176 | 0.740 |
Why?
| | Transcription Factors | 4 | 2022 | 1570 | 0.730 |
Why?
| | Tumor Suppressor Proteins | 3 | 2021 | 289 | 0.720 |
Why?
| | Peptide Hydrolases | 1 | 2020 | 108 | 0.710 |
Why?
| | Salivary Glands | 1 | 2019 | 32 | 0.690 |
Why?
| | Drugs, Investigational | 1 | 2019 | 31 | 0.680 |
Why?
| | Gastrula | 3 | 2004 | 21 | 0.680 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 180 | 0.660 |
Why?
| | DNA Replication | 3 | 2010 | 211 | 0.640 |
Why?
| | Nuclear Proteins | 4 | 2009 | 597 | 0.630 |
Why?
| | Pyrophosphatases | 1 | 2017 | 22 | 0.620 |
Why?
| | E2F1 Transcription Factor | 2 | 2024 | 56 | 0.610 |
Why?
| | Microtubule-Associated Proteins | 2 | 2009 | 188 | 0.560 |
Why?
| | Disease Models, Animal | 5 | 2020 | 3730 | 0.560 |
Why?
| | Gene Expression Regulation, Developmental | 6 | 2022 | 814 | 0.550 |
Why?
| | Models, Animal | 1 | 2017 | 363 | 0.550 |
Why?
| | Signal Transduction | 6 | 2023 | 4709 | 0.540 |
Why?
| | Autophagy | 1 | 2018 | 315 | 0.510 |
Why?
| | MicroRNAs | 2 | 2014 | 637 | 0.510 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 189 | 0.500 |
Why?
| | Methyl Methanesulfonate | 3 | 2010 | 6 | 0.490 |
Why?
| | Research | 1 | 2017 | 411 | 0.490 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2009 | 407 | 0.490 |
Why?
| | Epithelial Cells | 2 | 2017 | 963 | 0.480 |
Why?
| | Mutation | 12 | 2020 | 3457 | 0.470 |
Why?
| | Heterozygote | 3 | 2024 | 262 | 0.460 |
Why?
| | Mutagens | 3 | 2010 | 17 | 0.460 |
Why?
| | DNA-Binding Proteins | 6 | 2022 | 1346 | 0.430 |
Why?
| | Genome, Insect | 1 | 2012 | 23 | 0.430 |
Why?
| | Neuropeptides | 2 | 2009 | 68 | 0.420 |
Why?
| | Chromosome Aberrations | 2 | 2024 | 136 | 0.420 |
Why?
| | Cyclin A | 2 | 2001 | 15 | 0.400 |
Why?
| | Maytansine | 1 | 2011 | 13 | 0.400 |
Why?
| | DNA, Satellite | 1 | 2010 | 17 | 0.390 |
Why?
| | Paclitaxel | 1 | 2012 | 195 | 0.390 |
Why?
| | Hydrozoa | 1 | 2010 | 1 | 0.390 |
Why?
| | E2F2 Transcription Factor | 1 | 2010 | 15 | 0.380 |
Why?
| | Membrane Proteins | 1 | 2017 | 1055 | 0.380 |
Why?
| | Heterochromatin | 1 | 2010 | 38 | 0.380 |
Why?
| | Metabolic Networks and Pathways | 1 | 2011 | 176 | 0.380 |
Why?
| | Cell Division | 3 | 2005 | 776 | 0.370 |
Why?
| | Biology | 1 | 2011 | 83 | 0.360 |
Why?
| | Cell Survival | 4 | 2022 | 1047 | 0.360 |
Why?
| | Protein Kinases | 4 | 2021 | 310 | 0.340 |
Why?
| | Leprosy | 2 | 2019 | 10 | 0.330 |
Why?
| | Tyrosine | 1 | 2009 | 233 | 0.330 |
Why?
| | Teaching | 1 | 2011 | 236 | 0.330 |
Why?
| | Educational Measurement | 1 | 2011 | 289 | 0.320 |
Why?
| | Cyclin E | 2 | 2007 | 21 | 0.320 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1166 | 0.310 |
Why?
| | Cell Movement | 2 | 2019 | 896 | 0.300 |
Why?
| | Phosphorylation | 7 | 2009 | 1633 | 0.300 |
Why?
| | Humans | 26 | 2024 | 118972 | 0.290 |
Why?
| | Genes, cdc | 3 | 2006 | 10 | 0.270 |
Why?
| | Students | 1 | 2011 | 509 | 0.270 |
Why?
| | Telomere | 2 | 2006 | 204 | 0.270 |
Why?
| | CDC2 Protein Kinase | 2 | 2005 | 27 | 0.270 |
Why?
| | Anaphase | 2 | 2005 | 12 | 0.270 |
Why?
| | Metaphase | 2 | 2005 | 28 | 0.260 |
Why?
| | Gene Expression Regulation | 3 | 2009 | 2445 | 0.260 |
Why?
| | Head and Neck Neoplasms | 2 | 2020 | 471 | 0.260 |
Why?
| | Chromosomal Instability | 1 | 2004 | 18 | 0.250 |
Why?
| | Tubulin | 1 | 2005 | 122 | 0.250 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2004 | 18 | 0.240 |
Why?
| | Curriculum | 1 | 2011 | 910 | 0.240 |
Why?
| | Arthropods | 1 | 2004 | 9 | 0.240 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2003 | 4 | 0.240 |
Why?
| | Flow Cytometry | 3 | 2022 | 1085 | 0.240 |
Why?
| | Vertebrates | 1 | 2004 | 59 | 0.230 |
Why?
| | Telomere-Binding Proteins | 1 | 2004 | 87 | 0.230 |
Why?
| | Organogenesis | 1 | 2003 | 54 | 0.230 |
Why?
| | Cytoskeleton | 1 | 2004 | 181 | 0.220 |
Why?
| | Immunoprecipitation | 3 | 2009 | 161 | 0.210 |
Why?
| | Cell Proliferation | 5 | 2017 | 2275 | 0.210 |
Why?
| | Gene Expression | 2 | 2018 | 1489 | 0.210 |
Why?
| | Cell Line | 4 | 2023 | 2707 | 0.210 |
Why?
| | Cell Separation | 2 | 2022 | 296 | 0.210 |
Why?
| | Protein Biosynthesis | 2 | 2015 | 397 | 0.200 |
Why?
| | Cell Plasticity | 1 | 2022 | 24 | 0.200 |
Why?
| | Microscopy, Confocal | 4 | 2007 | 314 | 0.200 |
Why?
| | Checkpoint Kinase 2 | 4 | 2010 | 23 | 0.200 |
Why?
| | Neurofibromin 2 | 2 | 2021 | 3 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 740 | 0.200 |
Why?
| | Alleles | 2 | 2020 | 832 | 0.200 |
Why?
| | Cell Line, Tumor | 4 | 2020 | 2851 | 0.200 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 40 | 0.190 |
Why?
| | Phthalazines | 1 | 2020 | 47 | 0.190 |
Why?
| | Blotting, Western | 4 | 2009 | 1194 | 0.190 |
Why?
| | Intracellular Space | 1 | 2020 | 69 | 0.190 |
Why?
| | Cetuximab | 1 | 2020 | 99 | 0.190 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 26 | 0.180 |
Why?
| | RNA Interference | 3 | 2019 | 460 | 0.180 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 47 | 0.180 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 76 | 0.180 |
Why?
| | Biological Evolution | 1 | 2004 | 443 | 0.180 |
Why?
| | Diacylglycerol Kinase | 1 | 2019 | 5 | 0.180 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2020 | 190 | 0.180 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 360 | 0.180 |
Why?
| | rac GTP-Binding Proteins | 1 | 2019 | 36 | 0.180 |
Why?
| | Radiobiology | 1 | 2019 | 4 | 0.170 |
Why?
| | DNA | 2 | 2005 | 1388 | 0.170 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 220 | 0.170 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2000 | 145 | 0.170 |
Why?
| | Embryonic Development | 1 | 2000 | 118 | 0.170 |
Why?
| | Cancer Vaccines | 1 | 2020 | 139 | 0.170 |
Why?
| | Adjuvants, Immunologic | 1 | 2020 | 207 | 0.170 |
Why?
| | Antigens, Neoplasm | 1 | 2020 | 228 | 0.160 |
Why?
| | Molecular Imaging | 1 | 2019 | 54 | 0.160 |
Why?
| | Checkpoint Kinase 1 | 4 | 2006 | 27 | 0.160 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2018 | 155 | 0.160 |
Why?
| | Piperazines | 1 | 2020 | 316 | 0.160 |
Why?
| | Phenotype | 3 | 2018 | 3003 | 0.160 |
Why?
| | Transients and Migrants | 1 | 2017 | 22 | 0.160 |
Why?
| | S Phase | 2 | 2010 | 74 | 0.160 |
Why?
| | Gene Silencing | 2 | 2016 | 177 | 0.150 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 401 | 0.150 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 292 | 0.150 |
Why?
| | Protein Transport | 1 | 2018 | 412 | 0.150 |
Why?
| | Cell Lineage | 1 | 2018 | 318 | 0.150 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 356 | 0.150 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 24 | 0.140 |
Why?
| | Cell Polarity | 1 | 2017 | 133 | 0.140 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 336 | 0.140 |
Why?
| | Immunotherapy | 1 | 2020 | 493 | 0.140 |
Why?
| | Cost of Illness | 1 | 2017 | 258 | 0.130 |
Why?
| | Receptors, TIE | 1 | 2015 | 1 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2019 | 4077 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2874 | 0.130 |
Why?
| | Genetic Testing | 1 | 2017 | 389 | 0.130 |
Why?
| | Fluorescent Antibody Technique | 2 | 2005 | 410 | 0.120 |
Why?
| | Morphogenesis | 2 | 2005 | 167 | 0.120 |
Why?
| | HeLa Cells | 1 | 2015 | 583 | 0.120 |
Why?
| | Time Factors | 5 | 2005 | 6412 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 290 | 0.120 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2004 | 111 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 628 | 0.110 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2020 | 129 | 0.110 |
Why?
| | X-Rays | 2 | 2004 | 26 | 0.110 |
Why?
| | Glioma | 1 | 2015 | 306 | 0.100 |
Why?
| | Brain | 1 | 2004 | 2490 | 0.100 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 23 | 0.100 |
Why?
| | Tuberous Sclerosis | 1 | 2011 | 38 | 0.100 |
Why?
| | HCT116 Cells | 1 | 2011 | 68 | 0.100 |
Why?
| | Embryology | 1 | 2011 | 2 | 0.100 |
Why?
| | Mental Disorders | 1 | 2019 | 939 | 0.100 |
Why?
| | Mitotic Index | 1 | 2010 | 27 | 0.100 |
Why?
| | Mice | 5 | 2020 | 15520 | 0.100 |
Why?
| | Drug Design | 1 | 2011 | 160 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 770 | 0.090 |
Why?
| | Green Fluorescent Proteins | 2 | 2008 | 395 | 0.090 |
Why?
| | Goals | 1 | 2011 | 167 | 0.090 |
Why?
| | Peer Group | 1 | 2011 | 207 | 0.090 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 146 | 0.090 |
Why?
| | Biological Products | 1 | 2012 | 170 | 0.090 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 2071 | 0.090 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2009 | 363 | 0.080 |
Why?
| | Molecular Sequence Data | 2 | 2003 | 2871 | 0.080 |
Why?
| | Quality of Life | 1 | 2019 | 2366 | 0.080 |
Why?
| | Biomarkers | 1 | 2018 | 3588 | 0.080 |
Why?
| | Kinetochores | 1 | 2008 | 44 | 0.080 |
Why?
| | Gene Deletion | 2 | 2015 | 361 | 0.080 |
Why?
| | China | 2 | 2019 | 175 | 0.080 |
Why?
| | Survival Analysis | 1 | 2011 | 1267 | 0.080 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 142 | 0.080 |
Why?
| | Gene Dosage | 1 | 2008 | 136 | 0.080 |
Why?
| | Xenopus | 2 | 2005 | 104 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1022 | 0.080 |
Why?
| | E2F Transcription Factors | 1 | 2007 | 55 | 0.070 |
Why?
| | Learning | 1 | 2011 | 374 | 0.070 |
Why?
| | Cytokinesis | 1 | 2007 | 46 | 0.070 |
Why?
| | Gastrin-Releasing Peptide | 1 | 2005 | 6 | 0.070 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2006 | 30 | 0.070 |
Why?
| | Chromatography, Affinity | 1 | 2005 | 85 | 0.070 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 106 | 0.070 |
Why?
| | Microscopy, Fluorescence | 2 | 2005 | 412 | 0.070 |
Why?
| | Centrosome | 1 | 2005 | 59 | 0.070 |
Why?
| | Acid Anhydride Hydrolases | 1 | 2004 | 5 | 0.060 |
Why?
| | Transgenes | 1 | 2005 | 174 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2012 | 2657 | 0.060 |
Why?
| | DNA Repair Enzymes | 1 | 2004 | 23 | 0.060 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2004 | 62 | 0.060 |
Why?
| | Cleavage Stage, Ovum | 1 | 2004 | 7 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2006 | 828 | 0.060 |
Why?
| | Models, Genetic | 2 | 2006 | 595 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 755 | 0.060 |
Why?
| | Egg Proteins | 1 | 2004 | 19 | 0.060 |
Why?
| | Female | 7 | 2020 | 61564 | 0.060 |
Why?
| | Retinoblastoma Protein | 1 | 2004 | 52 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2004 | 32 | 0.060 |
Why?
| | Embryonic and Fetal Development | 1 | 2004 | 95 | 0.060 |
Why?
| | Invertebrates | 1 | 2004 | 22 | 0.060 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 76 | 0.060 |
Why?
| | Gene Targeting | 1 | 2004 | 80 | 0.060 |
Why?
| | Fertilization | 1 | 2004 | 43 | 0.060 |
Why?
| | Macromolecular Substances | 1 | 2004 | 201 | 0.060 |
Why?
| | X Chromosome | 1 | 2003 | 47 | 0.060 |
Why?
| | Models, Anatomic | 1 | 2004 | 94 | 0.060 |
Why?
| | Crosses, Genetic | 1 | 2003 | 138 | 0.060 |
Why?
| | Substrate Specificity | 1 | 2004 | 371 | 0.060 |
Why?
| | Body Patterning | 1 | 2004 | 131 | 0.060 |
Why?
| | Sequence Alignment | 1 | 2003 | 336 | 0.050 |
Why?
| | DNA Transposable Elements | 1 | 2003 | 102 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 372 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 982 | 0.050 |
Why?
| | Recombination, Genetic | 1 | 2003 | 173 | 0.050 |
Why?
| | Telomerase | 1 | 2004 | 207 | 0.050 |
Why?
| | Fertility | 1 | 2003 | 135 | 0.050 |
Why?
| | Mammals | 1 | 2004 | 253 | 0.050 |
Why?
| | Structure-Activity Relationship | 1 | 2003 | 522 | 0.050 |
Why?
| | Mass Spectrometry | 1 | 2005 | 681 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 408 | 0.050 |
Why?
| | Saccharomyces cerevisiae | 1 | 2005 | 495 | 0.050 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 15 | 0.050 |
Why?
| | Temperature | 1 | 2004 | 622 | 0.050 |
Why?
| | Amino Acid Motifs | 1 | 2001 | 200 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2020 | 46 | 0.050 |
Why?
| | Male | 5 | 2019 | 57801 | 0.050 |
Why?
| | Ubiquitination | 1 | 2021 | 87 | 0.050 |
Why?
| | Theranostic Nanomedicine | 1 | 2020 | 8 | 0.050 |
Why?
| | Blastoderm | 1 | 2000 | 1 | 0.050 |
Why?
| | Proteolysis | 1 | 2021 | 146 | 0.050 |
Why?
| | Clone Cells | 1 | 2020 | 248 | 0.050 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 154 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2003 | 580 | 0.050 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.050 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2000 | 67 | 0.050 |
Why?
| | Drug Synergism | 1 | 2020 | 339 | 0.050 |
Why?
| | Cell Size | 1 | 2000 | 86 | 0.050 |
Why?
| | Cyclins | 1 | 2000 | 82 | 0.040 |
Why?
| | Heat-Shock Response | 1 | 2000 | 59 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 1974 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2000 | 146 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 245 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1691 | 0.040 |
Why?
| | Phylogeny | 1 | 2003 | 816 | 0.040 |
Why?
| | Cisplatin | 1 | 2020 | 271 | 0.040 |
Why?
| | Base Sequence | 1 | 2003 | 2159 | 0.040 |
Why?
| | Cell Count | 1 | 2000 | 315 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 194 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 663 | 0.040 |
Why?
| | Nanotechnology | 1 | 2020 | 120 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 1945 | 0.040 |
Why?
| | Histones | 1 | 2004 | 552 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 200 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 197 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 156 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 4552 | 0.040 |
Why?
| | Microscopy | 1 | 2019 | 125 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2004 | 2680 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2020 | 569 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2020 | 442 | 0.040 |
Why?
| | Nanoparticles | 1 | 2020 | 325 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2000 | 446 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2015 | 12 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 1975 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1167 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1323 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 900 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1774 | 0.030 |
Why?
| | Middle Aged | 2 | 2019 | 27617 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4708 | 0.020 |
Why?
| | Adult | 2 | 2019 | 31512 | 0.020 |
Why?
| | G2 Phase | 1 | 2005 | 33 | 0.020 |
Why?
| | Hydroxyurea | 1 | 2005 | 30 | 0.020 |
Why?
| | Xenopus Proteins | 1 | 2005 | 67 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2005 | 268 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2006 | 371 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 10793 | 0.010 |
Why?
| | Aged | 1 | 2019 | 19657 | 0.010 |
Why?
| | RNA | 1 | 2005 | 833 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|